U.S. flag

An official website of the United States government

NM_000094.4(COL7A1):c.7723G>A (p.Gly2575Arg) AND COL7A1-related disorder

Germline classification:
Pathogenic (1 submission)
Last evaluated:
May 2, 2023
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV004529454.1

Allele description [Variation Report for NM_000094.4(COL7A1):c.7723G>A (p.Gly2575Arg)]

NM_000094.4(COL7A1):c.7723G>A (p.Gly2575Arg)

Gene:
COL7A1:collagen type VII alpha 1 chain [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
3p21.31
Genomic location:
Preferred name:
NM_000094.4(COL7A1):c.7723G>A (p.Gly2575Arg)
HGVS:
  • NC_000003.12:g.48568819C>T
  • NG_007065.1:g.31434G>A
  • NM_000094.3:c.[7723G>A]
  • NM_000094.4:c.7723G>AMANE SELECT
  • NP_000085.1:p.Gly2575Arg
  • NP_000085.1:p.Gly2575Arg
  • LRG_286t1:c.7723G>A
  • LRG_286:g.31434G>A
  • LRG_286p1:p.Gly2575Arg
  • NC_000003.11:g.48606252C>T
  • NM_000094.3:c.7723G>A
  • NM_000094.3:c.[7723G>A]
  • Q02388:p.Gly2575Arg
Protein change:
G2575R
Links:
UniProtKB: Q02388#VAR_001831; dbSNP: rs760891216
NCBI 1000 Genomes Browser:
rs760891216
Molecular consequence:
  • NM_000094.4:c.7723G>A - missense variant - [Sequence Ontology: SO:0001583]

Condition(s)

Name:
COL7A1-related disorder
Synonyms:
COL7A1-related condition; COL7A1- related disorders
Identifiers:

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV003934235Women's Health and Genetics/Laboratory Corporation of America, LabCorp
criteria provided, single submitter

(LabCorp Variant Classification Summary - May 2015)
Pathogenic
(May 2, 2023)
germlineclinical testing

PubMed (8)
[See all records that cite these PMIDs]

Citation Link

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Identical glycine substitution mutations in type VII collagen may underlie both dominant and recessive forms of dystrophic epidermolysis bullosa.

Almaani N, Liu L, Dopping-Hepenstal PJ, Lai-Cheong JE, Wong A, Nanda A, Moss C, Martinéz AE, Mellerio JE, McGrath JA.

Acta Derm Venereol. 2011 May;91(3):262-6. doi: 10.2340/00015555-1053.

PubMed [citation]
PMID:
21448560

Expanding the COL7A1 mutation database: novel and recurrent mutations and unusual genotype-phenotype constellations in 41 patients with dystrophic epidermolysis bullosa.

Kern JS, Kohlhase J, Bruckner-Tuderman L, Has C.

J Invest Dermatol. 2006 May;126(5):1006-12.

PubMed [citation]
PMID:
16484981
See all PubMed Citations (8)

Details of each submission

From Women's Health and Genetics/Laboratory Corporation of America, LabCorp, SCV003934235.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (8)

Description

Variant summary: COL7A1 c.7723G>A (p.Gly2575Arg) results in a non-conservative amino acid change located in the first fibronectin type III repeat domain (IPR003961) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 2.1e-05 in 191218 control chromosomes (gnomAD). The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. c.7723G>A has been reported in the literature in homozygous and compound heterozygous individuals affected with Dystrophic Epidermolysis Bullosa, Recessive (e.g., Shimizu_1996, Hovnanian_1997, Kern_2006, Almaani_2011, Matsumura_2018, Chiaverini_2014). These data indicate that the variant is very likely to be associated with disease. Several publications reported experimental evidence evaluating an impact on protein function, finding that the variant alters intermolecular interactions, thus affecting type VII collagen homotrimer processing and assembly (e.g., Brittingham_2005, Woodley_2008, Matsumura_2018). The following publications have been ascertained in the context of this evaluation (PMID: 21448560, 15509587, 24252097, 9326325, 16484981, 29229433, 8592061, 18450758). Three clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014, and all laboratories classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Oct 26, 2024